Grishina, A., Kulikova, I., Alieva, L., Dodson, A., Rowland, I., & Jin, J
Press release: Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy in a pill ) at ObesityWeek 2025, including demonstrated reductions in cardiovascular risk factors.* Retrieved from Rosenstock, J., Hsia, S., Ruiz, L
Common side effects include: Nausea Vomiting Diarrhea Decreased appetite Headache Stomach pain Fatigue Constipation Dizziness Heartburn Bloating and gas Low blood sugar (especially with insulin or sulfonylureas) Mood changes Serious, but rare side effects may include: Severe allergic reactions Pancreatitis Gallstones Kidney problems Worsening diabetic retinopathy Heart rate changes Suicidal thoughts or behaviors Thyroid cancer Bowel obstruction This is not a complete list
In addition, L-Carnitine by itself has been assessed as an exploratory endpoint